INTRODUCTION {#s1}
============

The TNM staging system for colorectal cancer (CRC) has been changed several times on the basis of a small expert panel consensus. The 5th edition TNM (TNM5) classification was the first to evaluate tumor deposits (TDs) and proposed the 3-mm rule in 1997 \[[@R1], [@R2]\]. The next edition (TNM6) concerned the presence of TDs in mesorectal and pericolic fat with the primary tumor, and defined TDs as positive lymph nodes (pLNs) when they had the form and smooth contour of lymph nodes (LNs) while irregular TDs with venous invasion remained in the T category \[[@R3], [@R4]\]. Recently, the presence of TDs has been reported as an important prognostic factor \[[@R5]-[@R9]\].

TDs were again taken into account in the American Joint Committee on Cancer (AJCC) 7th edition TNM classification (TNM7) for CRC, and a new pN1c category was proposed which states that T1 and T2 lesions that lack regional positive lymph node(s) but have tumor deposit(s) will be classified in addition as pN1c. However, it is not consistent in that in pN1c is also an option for pT3/4a tumors in the CRC staging table \[[@R10]\]. Despite the fact that TNM7 states that the number of TDs should be counted according to this categorization strategy, it does not point out the association of the number of TDs with stage III. There are also no clear guidelines on how to classify TDs in patients with pLNs and TDs simultaneously. This potentially impacts the accuracy of the classification and evaluation of the prognosis of CRC patients.

Recently, there has been discussion of the feasibility of TDs being counted as positive lymph nodes in the TNM staging system for CRC. Belt EJ et al. \[[@R11]\] declared lymph node negative CRC (stage II) with TDs should be classified and treated as stage III. Song YX et al. \[[@R5]\] reported that the counting of TDs as pLNs in the TNM staging system is potentially superior to the classification in the TNM7 to assess prognosis and survival for CRC patients. However, both of these studies included small numbers of patients (870 and 513 cases, respectively). In addition, in TNM7 gastric cancer staging, pathologic assessment of the regional pLNs entails their removal and histologic examination to evaluate the total number of nodes and TDs without evidence of residual LN tissue that were considered as pLN \[[@R12]\]. Thus, it is necessary to provide more effective data to validate the feasibility of counting the number of TDs as pLNs in the TNM classification criteria.

Here, we collected large-scale and multicenter data consisting of 4,121 stage II and III CRC patients who received initial radical surgery in order to investigate whether TDs can be counted as metastatic LNs using the AJCC TNM7 staging system for stage III CRC by calculating and comparing the 5-year disease-free survival (DFS) and overall survival (OS).

RESULTS {#s2}
=======

A total of 4,456 patients with CRC experienced initial radical surgery. According to the exclusion criteria, 180 cases with pTis/T1 stage, 45 with simultaneous distant metastasis, and 110 with other reasons were excluded. Finally, 4,121 cases were included in this retrospective study.

Clinicopathological characteristics of patients {#s2_1}
-----------------------------------------------

In total, we identified 17.4% (717/4,121) of patients with TDs. The male: female ratio was 1.33:1 (2,352/1,769). The median age was 58.0 ± 12.1 years (range: 14-87). Clinicopathological features are listed in Table [1](#T1){ref-type="table"}. In pN category (7th), the percentages of pN0-2b were 50.2%, 12.9%, 13.1%, 6.8%, 9.1% and 7.8%, respectively (*P* \< 0.0001). By contrast, the percentages of npN0-2b were 50.2%, 12.8%, 15.3%, 12.0% and 9.7%, respectively (*P* \< 0.0001). TDs were associated with preoperative carcinoembryonic antigen (CEA) or carbohydrate antigen 19-9 (CA19-9) levels, pT or pN category, npN category, differentiation grade, pathological category, and histological type (all *P* \< 0.05). Patients with and without TDs were similar with respect to gender, age, tumor location (colon *vs*. rectum), and tumor size (diameter) (all *P* \> 0.05). Additionally, the rates of patients with or without TDs who received adjuvant therapy were 17.0% and 18.2% (*P* = 0.343).

###### Association of TDs with clinical and pathological characteristics

  Variable                              All Patients (*n* = 4121)   Patients with TDs (*n* = 717)   *X*^2^   *P*              
  ------------------------------------- --------------------------- ------------------------------- -------- ------ --------- ----------
  Gender                                                                                                                      
  Male                                  2352                        57.1                            411      17.5   0.022     0.882
  Female                                1769                        42.9                            306      17.3             
  Age, year                                                                                                                   
  ≤60                                   2312                        56.1                            407      17.6   0.154     0.695
  \>60                                  1809                        43.9                            310      17.1             
  Tumor location                                                                                                              
  Colon                                 1449                        35.2                            278      19.2   0.51      0.475
  Rectum                                2671                        64.8                            439      16.4             
  Tumor size, diameter                                                                                                        
  ≤5.0 cm                               2866                        69.5                            508      17.7   0.68      0.410
  \>5.0 cm                              1254                        30.4                            209      16.7             
  Preoperative CEA levels                                                                                                     
  \<5.0 ng/ml                           2479                        60.2                            360      14.5   39.429    \<0.0001
  ≥5.0 ng/ml                            1161                        28.2                            238      20.5             
  Unknown                               481                         11.7                            119      24.7             
  Preoperative CA199 levels                                                                                                   
  \<29.0 u/ml                           2820                        68.4                            465      16.5   8.565     0.014
  ≥29.0 u/ml                            459                         11.1                            101      22               
  Unknown                               842                         20.4                            151      17.9             
  pT category (7th)                                                                                                           
  pT 2                                  128                         3.1                             4        3.1    66.154    \<0.0001
  pT 3                                  2851                        69.2                            323      11.3             
  pT 4                                  2242                        54.4                            390      17.4             
  pN category (7th)                                                                                                           
  pN 0                                  2070                        50.2                            0        0      61.773    \<0.0001
  pN 1a                                 533                         12.9                            100      18.8             
  pN 1b                                 539                         13.1                            124      23               
  pN 1c                                 282                         6.8                             282      100              
  pN 2a                                 374                         9.1                             80       21.4             
  pN 2b                                 323                         7.8                             131      40.6             
  npN category                                                                                                                
  npN 0                                 2070                        50.2                            0        0      128.185   \<0.0001
  npN 1a                                526                         12.8                            93       17.7             
  npN 1b                                629                         15.3                            214      34               
  npN 2a                                495                         12                              201      40.6             
  npN 2b                                401                         9.7                             209      52.1             
  Venous invasion                                                                                                             
  Yes                                   268                         6.5                             87       32.5   70.306    \<0.0001
  No                                    3853                        93.5                            630      16.4             
  Lymphatic invasion                                                                                                          
  Yes                                   26                          0.6                             12       46.2   11.528    0.001
  No                                    4095                        99.4                            705      17.2             
  Differentiation grade                                                                                                       
  Well                                  452                         11                              43       9.5    90.633    \<0.0001
  Moderately                            3213                        78                              523      16.3             
  Poorly                                456                         11.1                            146      32               
  Pathological category                                                                                                       
  Papillary or tubular adenocarcinoma   3856                        93.6                            660      17.1   8.991     0.003
  Mucinous adenocarcinoma               220                         5.3                             38       17.3             
  Signet ring cell cancer               45                          1.1                             19       42.2             
  Histological type                                                                                                           
  Protrude                              2733                        66.3                            477      17.5   17.184    \<0.0001
  Ulcer                                 1151                        27.9                            177      15.4             
  Infiltrative                          237                         5.8                             63       26.6             
  Adjuvant therapy                                                                                                            
  Yes                                   2796                        67.8                            476      17     0.899     0.343
  No                                    1325                        32.2                            241      18.2             

TDs resulted in stage migration {#s2_2}
-------------------------------

A total of 1,798 TDs were detected in 717 (17.4%) patients according to the 3-mm (TNM5) and contour (TNM6) rules. The mean TD diameter was 8.5 ± 3.2 mm (range: 3-24 mm). By changing the definition of TDs to being counted as positive LNs, stage migration was likely to happen. Not surprisingly, the presence of TDs was associated with advanced npN category as compared to pN category (Table [2](#T2){ref-type="table"}). TDs also more often presented with higher pT category (Table [1](#T1){ref-type="table"}). In Table [2](#T2){ref-type="table"}, we list stage migrations resulting from changes in the definition of TDs. Upstaging occurred in 330 of 717 patients (46.0%) with TDs that were in the pN category.

###### pN stage migration according to TDs counted as pLNs

  pN Category   npN Category   Sum               
  ------------- -------------- ----- ----- ----- ------
  pN1a          433            74    18    8     533
  pN1b                         458   63    18    539
  pN1c          93             97    85    7     282
  pN2a                               329   45    374
  pN2b                                     323   323
  Sum           526            629   495   401   2051

npN as a prognostic factor for DFS and OS {#s2_3}
-----------------------------------------

During follow-up, a total of 1215 patients (29.5%) suffered failure including 351 (8.5%) with local recurrence (LR), 973 (23.6%) with distant metastasis (DM) and 109 (2.6%) with both LR and DM. The 5-year DFS and OS rates for all 4,121 patients were 69.5% and 75.2%. The clinical and pathological data including the number of LR, DM, and all failures are listed in Table [2](#T2){ref-type="table"}. The 5-year DFS rates for npN0-2b were 83.6%, 72.4%, 65.6%, 45.7% and 26.0%, respectively (*P* \< 0.0001). By contrast, the 5-year DFS rates for pN0-2b were 83.6%, 71.4%, 57.8%, 69.9%, 39.5%, and 25.8%, respectively (*P* \< 0.0001). The 5-year OS for npN0-2b were 87.9%, 76.2%, 69.1%, 57.9% and 37.1%, respectively (*P* \< 0.0001). Compared to the npN category, the 5-year OS for pN0-2b were 87.9%, 74.3%%, 64.8%, 75.2%,50.1%, and 32.9%, respectively (*P* \< 0.0001).

Univariate analysis showed that the preoperative CEA or CA199 levels, pT, pN, npN, TDs, venous or lymphatic invasion, differentiation grade, pathological category and histological type were all correlated with DFS and OS (all *P* \< 0.0001). Additionally, age and adjuvant chemotherapy were prognostic factors for OS but not DFS. The DFS and OS curves for both npN and pN are shown in Figure [1](#F1){ref-type="fig"}. Considering the fact that the npN category can be considered as an adjusted classification of the pN category, making the pN and npN categories highly correlated, multivariate models for all patients were calculated separately for each variable to avoid potential bias (Tables [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}). As the result, both the npN and pN categories were identified as independent prognostic factors for DFS (HR 1.614, 95% CI 1.541 to 1.673; HR 1.604, 95% CI 1.533 to 1.679) and OS (HR 1.633, 95% CI 1.550 to 1.720; HR 1.470, 95% CI 1.410 to 1.532) by multivariate analyses (all *P* \< 0.0001).

###### The DFS and OS curves for npN and pN categories

**1A.** The 5-year DFS rates of npN0-2b were 83.6%, 72.4%, 65.6%, 45.7%, 26.0%,respectively (*P* \< 0.0001), and the 5-year DFS rates of each group from npN 0 to 2b were different (all *P* \< 0.05). **1B.** The 5-year DFS rates of pN0-2b were 83.6%, 71.4%, 57.8%, 69.9%, 39.5%, and 25.8%, respectively (*P* \< 0.0001). pN1a and 1c had similar 5-year DFS rates (*P* = 0.862). **1C.** The 5-year OS rates of npN0-2b were 87.9%, 76.2%, 69.1%, 57.9% and 37.1%, respectively (*P* \< 0.0001), and the 5-year DFS rates of each group from npN 0 to 2b were different (all *P* \< 0.05). **1D.** The 5-year OS rates of pN0-2b were 87.9%, 74.3%, 64.8%, 75.2%, 50.1% and 32.9%, respectively (*P* \< 0.0001), and the 5-year DFS rates of each group from pN 0 to 2b were different (all *P* \< 0.05). Of note, pN1c had a similar 5-year OS rate with pN1a (*P* = 0.303).
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###### Influence of different clinical and pathological factors on 5-year DFS and OS

  Variable                              No. of All patients   Local Recurrence   Distant Metastasis   All Failure   5-Years DFS Rate   *P*    5-Year OS Rate   *P*                        
  ------------------------------------- --------------------- ------------------ -------------------- ------------- ------------------ ------ ---------------- ------- ---------- ------- ----------
                                        4121                  351                8.5%                 973           23.6%              1215   29.5%            69.5%              75.2%   
  Gender                                                                                                                                                                                  
  Male                                  2352                  219                9.3%                 553           23.5%              713    30.3%            68.7%   0.081      74.9%   0.762
  Female                                1769                  132                7.5%                 420           24.7%              502    29.4%            70.6%              75.5%   
  Age, year                                                                                                                                                                               
  ≤60                                   2312                  173                7.5%                 535           24.1%              652    29.2%            71.5%   0.087      78.0%   \<0.0001
  \>60                                  1809                  178                9.8%                 438           24.2%              563    31.1%            66.9%              71.5%   
  Tumor location                                                                                                                                                                          
  Colon                                 1449                  34                 2.3%                 364           25.1%              381    26.3%            73.2%   0.065      76.1%   0.132
  Rectum                                2671                  317                11.9%                609           22.8%              834    31.2%            67.4%              74.7%   
  Tumor size, diameter                                                                                                                                                                    
  ≤5.0 cm                               2866                  240                8.4%                 670           23.4%              835    29.1%            70.1%   0.654      75.8%   0.251
  \>5.0 cm                              1254                  111                8.9%                 303           24.1%              380    30.3%            68.2%              73.9%   
  Preoperative CEA levels                                                                                                                                                                 
  \<5.0 ng/ml                           2479                  98                 8.4%                 463           18.7%              610    24.6%            75.0%   \<0.0001   80.7%   \<0.0001
  ≥5.0 ng/ml                            1161                  198                8.0%                 401           34.5%              454    39.1%            58.6%              64.3%   
  Unknown                               481                   55                 11.4%                109           22.7%              151    31.4%            67.0%              72.0%   
  Preoperative CA199 levels                                                                                                                                                               
  \<29.0 u/ml                           2820                  32                 7.0%                 490           20.8%              601    26.5%            73.1%   \<0.0001   81.3%   \<0.0001
  ≥29.0 u/ml                            459                   169                7.2%                 179           39.0%              195    42.5%            54.9%              54.5%   
  Unknown                               842                   55                 6.5%                 109           12.9%              151    17.9%            80.2%              72.0%   
  pT category (7th)                                                                                                                                                                       
  pT 2                                  128                   8                  6.2%                 20            15.6%              26     20.3%            78.5%   \<0.0001   82.8%   \<0.0001
  pT 3                                  2851                  141                8.1%                 253           14.4%              353    20.2%            79.2%              83.4%   
  pT 4                                  2242                  202                9.0%                 700           31.2%              836    37.3%            61.3%              68.1%   
  pN category (7th)                                                                                                                                                                       
  pN 0                                  2070                  106                5.1%                 252           12.2%              332    16.0%            83.6%   \<0.0001   87.9%   \<0.0001
  pN 1a                                 533                   39                 7.3%                 121           22.7%              149    28.0%            71.4%              74.3%   
  pN 1b                                 539                   43                 8.0%                 187           34.7%              215    39.1%            57.8%              64.8%   
  pN 1c                                 282                   42                 14.9%                47            16.7%              87     30.9%            69.9%              75.2%   
  pN 2a                                 374                   56                 15.0%                171           45.7%              207    55.3%            39.5%              50.1%   
  pN 2b                                 323                   65                 20.1%                195           40.6%              225    69.7%            25.8%              32.9%   
  npN category                                                                                                                                                                            
  npN 0                                 2070                  106                5.1%                 252           12.2%              332    16.0%            83.6%   \<0.0001   87.9%   \<0.0001
  npN 1a                                526                   32                 6.1%                 116           22.1%              141    26.8%            72.4%              76.2%   
  npN 1b                                629                   51                 8.1%                 179           28.5%              207    22.9%            65.6%              69.1%   
  npN 2a                                495                   72                 14.5%                198           40.0%              252    50.9%            45.7%              57.9%   
  npN 2b                                401                   90                 22.4%                228           56.9%              283    60.6%            26.0%              37.1%   
  Tumor deposits (TDs)                                                                                                                                                                    
  Positive                              717                   131                18.3%                281           39.2%              389    54.3%            44.6%   \<0.0001   57.7%   \<0.0001
  Negative                              3404                  220                6.5%                 692           20.3%              826    24.3%            74.9%              78.9%   
  Venous invasion                                                                                                                                                                         
  Yes                                   268                   47                 17.5%                136           50.7%              157    58.6%            36.8%   \<0.0001   45.7%   \<0.0001
  No                                    3853                  304                7.9%                 837           21.7%              1058   27.5%            71.7%              77.1%   
  Lymphatic invasion                                                                                                                                                                      
  Yes                                   26                    8                  30.8%                10            38.5%              16     61.5%            29.2%   \<0.0001   35.6%   \<0.0001
  No                                    4095                  343                9.4%                 963           23.5%              1199   29.3%            69.8%              75.4%   
  Differentiation grade                                                                                                                                                                   
  Well                                  452                   22                 4.9%                 54            11.9%              73     16.2%            82.7%   \<0.0001   88.2%   \<0.0001
  Moderately                            3213                  275                8.6%                 725           22.6%              922    28.7%            70.4%              75.8%   
  Poorly                                456                   54                 11.8%                194           42.5%              220    48.2%            50.0%              57.8%   
  Pathological category                                                                                                                                                                   
  Papillary or tubular adenocarcinoma   3856                  325                8.4%                 888           23.0%              1121   29.1%            69.9%   \<0.0001   75.9%   \<0.0001
  Mucinous adenocarcinoma               220                   20                 9.1%                 63            28.6%              68     30.9%            68.2%              70.1%   
  Signet ring cell cancer               45                    6                  13.7%                22            49.9%              26     57.8%            40.8%              41.5%   
  Histological type                                                                                                                                                                       
  Protrude                              2733                  230                8.4%                 561           20.5%              722    26.4%            73.0%   \<0.0001   78.5%   \<0.0001
  Ulcer                                 1151                  98                 8.5%                 322           28.0%              386    33.5%            64.8%              70.1%   
  Infiltrative                          237                   23                 9.7%                 90            38.0%              107    45.1%            52.1%              61.2%   
  Adjuvant therapy                                                                                                                                                                        
  Yes                                   2796                  228                8.2%                 672           24.0%              825    29.5%            70.1%   0.361      76.7%   0.002
  No                                    1325                  123                9.3%                 301           22.7%              390    29.4%            68.2%              71.8%   

###### Multivariate analysis for 5-year DFS and OS when npN category enrolled

  Variables               5-Year DFS   5-Year OS                                                
  ----------------------- ------------ ------------------ ---------- ------- ------------------ ----------
  Age                     ---          ---                ---        1.371   (1.181 to 1.592)   \<0.0001
  Preoperative CEA        0.901        (0.792 to 1.024)   0.111      0.970   (0.837 to 1.123)   0.683
  PreoperativeCA199       0.987        (0.844 to 1.154)   0.867      0.843   (0.711 to 0.994)   0.041
  pT category             1.461        (1.280 to 1.668)   \<0.0001   1.533   (1.312 to 1.791)   \<0.0001
  pN category             1.367        (1.313 to 1.422)   \<0.0001   1.462   (1.398 to 1.529)   \<0.0001
  TDs                     0.591        (0.509 to 0.687)   \<0.0001   1.103   (1.039 to 1.200)   0.036
  Venous invasion         0.729        (0.594 to 0.895)   0.003      0.816   (0.648to 1.027)    0.083
  Lymphatic invasion      0.455        (0.276 to 0.750)   0.002      0.555   (0.323 to 0.954)   0.033
  Differentiation grade   1.387        (1.209 to 1.591)   \<0.0001   1.425   (1.222 to 1.663)   \<0.0001
  Pathological category   1.112        (1.006 to 1.229)   0.037      1.160   (1.036 to 1.298)   0.010
  Histological type       0.924        (0.774 to 1.103)   0.381      1.131   (0.940 to 1.361)   0.193
  Adjuvant Chemotherapy   ---          ---                ---        1.660   (1.413 to 1.950)   \<0.0001

###### Multivariate analysis for 5-year DFS and OS when pN category enrolled

  Variables               5-Year DFS   5-Year OS                                                
  ----------------------- ------------ ------------------ ---------- ------- ------------------ ----------
  Age                     ---          ---                ---        1.346   (1.160 to 1.563)   \<0.0001
  Preoperative CEA        0.901        (0.793 to 1.023)   0.108      0.950   (0.822 to 1.099)   0.493
  Preoperative CA199      0.976        (0.837 to 1.138)   0.755      0.839   (0.709 to 0.993)   0.041
  pT category             1.448        (1.270 to 1.651)   0.000      1.517   (1.300 to 1.769)   \<0.0001
  npN category            1.519        (1.444 to 1.598)   \<0.0001   1.653   (1.560 to 1.752)   \<0.0001
  TDs                     0.665        (0.570 to 0.775)   \<0.0001   1.108   (1.007 to 1.202)   0.032
  Venous invasion         0.730        (0.595 to 0.897)   0.003      0.791   (0.629 to 0.995)   0.045
  Lymphatic invasion      0.466        (0.283 to 0.769)   0.003      0.534   (0.311 to 0.917)   0.023
  Differentiation grade   1.333        (1.163 to 1.529)   \<0.0001   1.384   (1.187 to 1.613)   \<0.0001
  Pathological category   1.094        (0.989 to 1.210)   0.082      1.140   (1.108 to 1.277)   0.023
  Histological type       0.936        (0.784 to 1.117)   0.463      1.139   (0.947 to 1.371)   0.168
  Adjuvant Chemotherapy   ---          ---                ---        1.747   (1.488 to 2.052)   \<0.0001

The pN and npN categories were calculated by Harrell\'s C statistic to identify which one had superior predictive capacity. The npN category (Harrell\'s C = 0.716, 95% CI: 0.709 to 0.728) was found to be superior to the pN category (Harrell\'s C = 0.707, 95% CI: 0.695 to 0.718) for DFS. Also, the npN category was a more accurate predictor than pN category for OS (Harrell\'s C = 719, 95% CI: 0.700 to 0.736; 712, 95% CI: 0.696 to 0.731, respectively). To identify whether one TD and one pLN had the same weight in patient outcome, we compared the 5-year DFS and OS rates for patients with pure pLNs with patients with pLNs plus TDs. The results are shown in Table [6](#T6){ref-type="table"} and indicate no prognostic heterogeneity meaning that TDs had the same weight as the pLNs (all *P* \< 0.05).

###### Influence of TDs on 5-year DFS and OS in subgroups of npN category

  npN Category   No. of All Patients   All Failure with TDs   All Failure without TDs   5-Years DFS Rate   5-Years OS Rate                      
  -------------- --------------------- ---------------------- ------------------------- ------------------ ----------------- ------------------ ------------------
  npN 1a         526                   27                     29.00%                    114                26.30%            72.1% *vs*.73.6%   76.0% *vs*.76.2%
  npN 1b         629                   73                     34.10%                    134                32.30%            65.4% *vs*.65.7%   68.9% *vs*.69.9%
  npN 2a         495                   107                    53.20%                    145                49.30%            44.8% *vs*.46.3%   57.3% *vs*.58.5%
  npN 2b         401                   150                    71.80%                    133                69.30%            25.4% *vs*.27.6%   36.8% *vs*.37.5%

Note: the 5-year DFS rates of the subgroups with or without TDs in npN1a, 1b, 2a, 2b were similar (all P \< 0.05), and the 5-year OS rates of the subgroups had the similar results (all P \< 0.05).

DISCUSSION {#s3}
==========

Changes in definitions of what should be considered as positive lymph nodes (pLNs) and tumor deposits (TDs) have been causing great confusion and having a large impact on patient prognosis and selection for postoperative chemoradiotherapy. Although tumor deposits are defined as focal aggregates of adenocarcinoma located in the pericolic or perirectal fat discontinuous with the primary tumor and unassociated with a lymph node, it is difficult to distinguish TDs and nodes. Thus, TNM5 proposed the 3-mm rule, which defined a tumor nodule \> 3mm in diameter without histological evidence of residual lymph node tissue as a TD \[[@R1]\]. However, this rule was reported as being based on unpublished data, which were not substantiated. In TNM6, the new definition of TDs based on contour replaced the 3-mm rule, and defined TDs to be classified as pLNs when they had the form and smooth contour of lymph nodes, while irregular TDs were classified in the pT category and as venous invasion \[[@R3]\]. Still, this contour rule lacks support from clinical evidences and reproducibility is poor because of the absence of appropriate guidelines \[[@R8]\].

Currently, the TNM7 proposed a novel pN category (pN1c) in stage III in the absence of lymph node (LN) metastasis which states T1 and T2 lesions that lack regional positive lymph node(s) but have tumor deposit(s) be classified in addition as pN1c, though it is not consistent in that in pN1c is also an option for pT3/4a tumors in the CRC staging table \[[@R10]\]. However, this new edition does not propose guidelines on the definition of TDs, which might impact reproducibility because of subjective opinion from pathologists. Although the TNM staging system changed several times with lack of appropriate guidelines, it is still the most important determinant of prognosis in CRC and it is the basis for the patient management guidelines that influence most patient management decisions \[[@R5]\].

The prevalence of TDs ranges from 6% to 64% in CRC and 17% to 55% in colon cancer \[[@R13]\]. The TNM7 abandoned the 3-mm rule and retained the contour rule so that classification of TDs is left to the discretion of the pathologists and pN1c is designated for TDs. However, when we investigated the use of the new definition for TDs, we found that all studies selected TDs depending, in part, on the definition. In other words, TDs selection is still lacking in guidelines. Still, it is difficult to distinguish pLNs and TDs especially when nodes are replaced completely by tumor cells. In fact, the TNM7 gastric cancer staging system has considered TDs as metastatic lymph nodes and the number of TDs was included for pathologic staging \[[@R12]\]. Additionally, TDs were considered as pLNs in Japanese classification of CRC \[[@R14]\]. Song YX et al \[[@R5]\] declared that tumor deposits can be counted as metastatic lymph nodes in TNM staging system for CRC. Based on the above evidence, we attempted to consider all TDs as pLNs and re-designate the pN category.

In the present study, we considered all TDs as pLNs and the npN category was determined by the number of pLNs plus TDs. By using the npN category, we simplified the node category and investigated the feasibility and effects. The 5-year DFS and OS rates of patients with or without TDs were 44.6% *vs*. 74.9% and 57.7% *vs*. 78.9% (*P* \< 0.0001, respectively), which indicatapproved that patients with TDs had a worse DFS and OS compared with patients without TDs. This result was similar with to a previous study \[[@R8]\]. By using univariateble and multivariateble analyses, we concluded that TDs could be potentially an independent and adverse prognostic factor for colorectal cancer. Of note, in multivariable analysis, we found that both the npN and pN category were independent predictors for long-term outcome, including DFS and OS in CRC. And then we declared that, however, the npN category was superior to the pN category for DFS (Harrell\'s C = 0.716, 95% CI: 0.709 to 0.728 *vs*. 0.707, 95% CI: 0.695 to 0.718) and OS (Harrell\'s C = 719, 95% CI: 0.700 to 0.736 *vs*. 0.712, 95% CI: 0.696 to 0.731). Thus, we proposed that the TDs can be counted as pLNs in TNM staging system and the npN category is feasible and superior to the pN category for predicting the long-term outcomes in CRC.

The origins of TDs remain controversial. Some studies propose that 3 types of TDs can be identified. They define TDs as "vascular invasion type," "TDs other than the vascular invasion type," and "tumor deposits, extramural venous and perineural types of invasion" \[[@R15], [@R16]\]. Recent studies have declared strong correlations between the presence of TDs and vascular invasion \[[@R7], [@R17], [@R18]\]. However, in the present study, we did not differentiate between types of TDs and reported that 32.5% (87/268) of the TDs was with venous invasion, which was lower than previous studies. Besides, 46.2% (12/26) of the patients with TDs also had lymphatic invasion. In our study, we differentiated venous invasion from lymphatic invasion by hematoxylin-eosin (H-E) staining, which may reduce the accuracy of recognizing venous and lymphatic invasion. In fact, many other factors such as the histological sectioning, which is only a 2-demensional sample of the 3-demensional structure, could cause us to underestimate the association of TDs with vessels.

Whether or not TDs should be considered pLNs or satellite tumor nodules for the purposes of staging may be difficult to determine. It is thus necessary and reasonable to consider TDs as pLNs. Using the npN category, pathologists and clinicians can simplify the TNM staging system and make suitable suggestions for patient postoperative treatment.

The results from this study are constrained by all the flaws and biases inherent to a nonrandomized trial, although this study included large-scale and multicenter data. Additionally, there are no clear and regular guidelines on how to identify the TDs from lymph nodes, which also may potentially influence the conclusions. The ideal trial design to investigate TDs according to sections of whole specimens would be a prospective clinical trial, which may be helpful to get more reliable data.

In sum, we found that it was feasible to consider TDs as positive lymph nodes in the pN category for evaluating the prognoses of CRC patients, and the npN category was potentially superior to the 7th pN category for predicting the disease-free and overall survival of advanced CRC patients. Whether the npN category has any additional significant practical impact on patients management needs more data to validate.

PATIENTS AND METHODS {#s4}
====================

Ethics considerations {#s4_1}
---------------------

Ethical approval was obtained from the appropriate ethics committees of all participating study sites before the enrolment of patients started. Informed consent was obtained by the investigator at each center from all patients before patient enrollment.

Patients {#s4_2}
--------

A total of 4,121 patients with stage II and III colorectal adenocarcinoma who received an initial radical surgery were identified at seven study centers in China between January 2004 and December 2011, and all relevant data were retrospectively collected including age, gender, serum CEA and CA199 levels, date of surgery, location of the primary tumor (colon and rectal), date and site of recurrence, pathological result, adjuvant chemoradiotherapy and cause of death (CRC related or other cause). We defined colon cancer including tumors locating in cecum to sigmoid colon, and rectal cancer containing tumors locating in rectum or rectosigmoid junction according to the definition from Chok KS et al. \[[@R19]\].

The exclusion criteria were as follows: 1) patients who received neoadjuvant chemoradiotherapy (NCRT, resulting in less nodes detection in specimens); 2) patients with distant metastasis such as liver metastasis found pre- or perioperatively; 3) patients with multiple adenocarcinomas of colon and rectum; 4) patients with synchronous or metachronous tumors; 5) patients who had suffered from colorectal cancer before; 6) patients who died in the immediate postoperative period (within 1 month); 7) patients with positive circumferential resection margins; and 8) patients without complete pathological slides.

Treatments {#s4_3}
----------

All patients initially received R0 resection without preoperative radiotherapy and/or chemotherapy. For rectal cancer patients, the standard total mesorectal excision was performed. After surgery, patients were treated with radiotherapy and/or chemotherapy or not according to body situation and TNM staging system except some patients who rejected adjuvant therapy. Patients with rectal cancer received adjuvant chemoradiotherapy (40-50Gy/2Gy/20-25F and Xeloda basically), while colon cancer patients were treated with Xeloda and 5-Fu regimens basically. 1325 patients did not received adjuvant therapy, including 83.1% (1101/1325) of patients who were in low risk, and other 16.9% (224/1325) who were in high risk (venous invasion, lymphatic invasion, poor differentiation, or advanced stage) but rejected adjuvant therapy (46.4%, 104/224), or were in poor body situation and could not tolerate adjuvant therapy (53.6%, 120/224).

Pathologic examination {#s4_4}
----------------------

Sections from all resected specimens were examined by local pathologists from seven hospitals. The standardized protocol included determination of the AJCC TNM classification, stage grouping, differentiation degree, histological type, pathological number of examined and involved lymph nodes, and presence or absence of lymphatic or venous invasion. All slides were reviewed for the presence of TDs, defined as either macroscopic or microscopic depositions of carcinoma, without any residual lymph node structures. TDs were assessed using the 3-mm (TNM5) and contour (TNM6) rules \[[@R7], [@R8]\]. For a regular tumor nodule, we classify it as a positive LN. For an irregular node without any residual tissues of LN we consider it as a TD if the diameter \> 3mm measured by a ruler, otherwise, we consider the irregular node as pT3 if the diameter ≤3mm. The reference pathologist tested pathological sections and then recorded the findings in a standardized document.

Classification methods {#s4_5}
----------------------

All patients were classified depending on TNM7, and then we counted TDs as pLNs in a new pN category. In this study, the pN category which combined with the number of TDs was recorded as npN category \[[@R5]\].

Follow-up {#s4_6}
---------

The follow-up result was collected from all seven hospitals\'database. The end point of follow-up was May 2015. The median time of follow-up was 66 months (range: 2-136 months).

Statistical analysis {#s4_7}
--------------------

Local recurrence and distant metastasis analyses were performed for all eligible patients who received R0 resection without distant metastasis found at time of surgery. All time-to-event end points were measured from date of radical surgery. Disease-free survival (DFS) and overall survival (OS) was calculated from radical resection to finding evidence of local recurrence and/or distant metastasis. Statistical analysis was performed using SPSS software (version 19). Differences were evaluated with the log-rank test. Analyses for local recurrence and distant metastasis were calculated as cumulative incidences. Mutivariate models were performed using the Cox proportional hazards model. All significant variables in the univariate analysis were included in multivariate Cox regression models in a forward-step procedure. The variables were entered in the order according to clinical relevance into the regression models with increasing complexity, and significance was assessed using analysis of variance analysis. The predictive power of the individual models was evaluated using Harrell\'C statistic. A model with perfect predictive capacity (sensitivity and specificity of 100%) would have a Harrell\'C statistic of 1.00 and the highest Harrell\'C statistic was chosen as the best model \[[@R20]\]. A two-sided p value less than 0.05 was considered to be significant.
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